207_Combined course Presentations

Oligometastatic NSCLC

 About 50% of all patients with NSCLC present with metastatic disease at the time of diagnosis

 Platinum-based doublet chemotherapy can improve quality of life and extend survival , but the prognosis of patients with metastatic NSCLC remains extremely poor , with MST from 8 to 11 months

 Moreover, the predominant pattern of failure in patients with localized NSCLC is distant metastatic spread